ABBV ▲ +0.6% - AbbVie Inc.
$ABBV - Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
05-OCT-2026 03:00 PM ET
Share this post
More filings for $ABBV
ABBV ▲ +0.5% - AbbVie Inc.Oct 23, 2026ABBV ▲ +1.2% - AbbVie Inc.Oct 22, 2026ABBV ▼ -0.6% - AbbVie Inc.Oct 21, 2026ABBV ▲ +0.4% - AbbVie Inc.Oct 20, 2026ABBV ▲ +1.3% - AbbVie Inc.Oct 19, 2026ABBV ▲ +1.3% - AbbVie Inc.Oct 17, 2026
View full $ABBV filing history →💬 Comments
Loading comments…
Leave a comment